Europe — EMA
Ocrevus (Ocrelizumab)
Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a solution for intravenous infusion use. It modifies disease activity in adults with multiple sclerosis.
Request sourcing
What is Ocrelizumab?
Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a solution for intravenous infusion use. It modifies disease activity in adults with multiple sclerosis. GNH USA supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Ocrelizumab used for?
Ocrevus is a disease‑modifying therapy that targets the multiple sclerosis pathway.
- Relapsing forms of multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression. - Primary progressive multiple sclerosis: delays the onset of confirmed disability worsening. - Secondary progressive multiple sclerosis: provides benefit in slowing the accumulation of disability. - Clinically isolated syndrome: may delay conversion to clinically definite multiple sclerosis.
What are the side effects of Ocrelizumab?
Ocrevus may elicit a range of adverse reactions, from mild to serious.
Common Side Effects: - Infusion‑related reactions: fever , chills , itching , rash , nausea. - Upper respiratory tract infections. - Headache. - Fatigue. - Mild decrease in white blood cell counts.
Serious or Rare Side Effects: - Severe infusion reactions including anaphylaxis. - Opportunistic infections such as tuberculosis and pseudomon infection . - Hepatitis and liver enzyme elevations . - Progressive t un un un un un un un un un un un un un un un un un un un . -
